Literature DB >> 22991066

Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy.

Susan L Greenspan1, Julie Wagner, Joel B Nelson, Subashan Perera, Cynthia Britton, Neil M Resnick.   

Abstract

Androgen deprivation therapy (ADT), a treatment for prostate cancer, is associated with bone loss and fractures. Dual-energy X-ray absorptiometry (DXA)-measured bone mineral density does not assess vertebral fractures (VF). High-resolution micro-magnetic resonance imaging (HR-MRI) assesses bone microarchitecture and provides structural information. To determine if VF identification increased the diagnosis of osteoporosis beyond DXA and if HR-MRI demonstrated skeletal deterioration in men with VF, we cross-sectionally studied 137 men aged ≥ 60 years with nonmetastatic prostate cancer on ADT for ≥ 6 months. Vertebral fracture assessment (VFA) by DXA was confirmed with X-rays. HR-MRI of the wrist included bone volume to total volume (BV/TV), surface density (trabecular plates), surface/curve ratio (plates/rods), and erosion index (higher depicts deterioration). VF were found in 37% of men; the majority were unknown. Seven percent of participants were classified as osteoporotic by hip or spine DXA. Thirty-seven percent of men without osteoporosis by DXA had VF identified, suggesting that 90% of patients with clinical osteoporosis would have been misclassified by DXA alone. By ANOVA comparison across VF grades, the BV/TV, surface density, and spine, hip, and wrist DXA were lower, and erosion index was higher in men with moderate-severe VF compared with lesser grades (all p < 0.05). By unadjusted ROC analysis, the addition of HR-MRI to DXA at the spine, hip, and femoral neck added substantially (AUC increased 0.831 to 0.902, p < 0.05) to prediction of moderate-severe vertebral fracture. HR-MRI indices were associated with spine, hip, and wrist DXA measures (p < 0.01). Longer duration of ADT was associated with lower BV/TV, surface density, and surface/curve ratio (p < 0.05). ADT for men with prostate cancer is associated with silent VF. DXA alone leads to misclassifications of osteoporosis, which can be avoided by VF assessment. HR-MRI provides a novel technique to assess deterioration of structural integrity in men with VF and adds micro-structural information.
Copyright © 2013 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22991066      PMCID: PMC3889112          DOI: 10.1002/jbmr.1771

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  35 in total

1.  What can be expected from risk scores for predicting postoperative nausea and vomiting?

Authors:  C C Apfel; P Kranke; C A Greim; N Roewer
Journal:  Br J Anaesth       Date:  2001-06       Impact factor: 9.166

Review 2.  Role of magnetic resonance for assessing structure and function of trabecular bone.

Authors:  Felix W Wehrli; Punam K Saha; Bryon R Gomberg; Hee Kwon Song; Peter J Snyder; Maria Benito; Alex Wright; Richard Weening
Journal:  Top Magn Reson Imaging       Date:  2002-10

Review 3.  Mechanisms of osteoporosis therapy: a bone strength perspective.

Authors:  Mary L Bouxsein
Journal:  Clin Cornerstone       Date:  2003

4.  Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group.

Authors:  K E Ensrud; D E Thompson; J A Cauley; M C Nevitt; D M Kado; M C Hochberg; A C Santora; D M Black
Journal:  J Am Geriatr Soc       Date:  2000-03       Impact factor: 5.562

5.  Digital topological analysis of in vivo magnetic resonance microimages of trabecular bone reveals structural implications of osteoporosis.

Authors:  F W Wehrli; B R Gomberg; P K Saha; H K Song; S N Hwang; P J Snyder
Journal:  J Bone Miner Res       Date:  2001-08       Impact factor: 6.741

6.  Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer.

Authors:  M G Oefelein; V Ricchuiti; W Conrad; A Seftel; D Bodner; H Goldman; M Resnick
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

7.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.

Authors:  Marc C Hochberg; Susan Greenspan; Richard D Wasnich; Paul Miller; Desmond E Thompson; Philip D Ross
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

8.  Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

Authors:  Steven R Cummings; David B Karpf; Fran Harris; Harry K Genant; Kristine Ensrud; Andrea Z LaCroix; Dennis M Black
Journal:  Am J Med       Date:  2002-03       Impact factor: 4.965

9.  Risk of fracture after androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

10.  National practice patterns and time trends in androgen ablation for localized prostate cancer.

Authors:  Matthew R Cooperberg; Gary D Grossfeld; Deborah P Lubeck; Peter R Carroll
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506

View more
  9 in total

1.  Pattern of Tumour Spread of Common Primary Tumours as Seen on Magnetic Resonance Imaging.

Authors:  David Laszlo Tarnoki; Adam Domonkos Tarnoki; Susanne Ohlmann-Knafo; Dirk Pickuth
Journal:  Pathol Oncol Res       Date:  2015-08-30       Impact factor: 3.201

2.  ADT in men with prostate cancer leads to osteoporosis and vertebral fractures.

Authors: 
Journal:  Bonekey Rep       Date:  2012-12-12

Review 3.  MRI assessment of bone structure and microarchitecture.

Authors:  Gregory Chang; Sean Boone; Dimitri Martel; Chamith S Rajapakse; Robert S Hallyburton; Mitch Valko; Stephen Honig; Ravinder R Regatte
Journal:  J Magn Reson Imaging       Date:  2017-02-06       Impact factor: 4.813

Review 4.  Estrogens and Androgens in Skeletal Physiology and Pathophysiology.

Authors:  Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

5.  Influence of Metastatic Bone Lesion Type and Tumor Origin on Human Vertebral Bone Architecture, Matrix Quality, and Mechanical Properties.

Authors:  Stacyann Bailey; Marc A Stadelmann; Philippe K Zysset; Deepak Vashishth; Ron N Alkalay
Journal:  J Bone Miner Res       Date:  2022-04-05       Impact factor: 6.390

6.  Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice.

Authors:  Gherardo Mazziotti; Walter Vena; Rebecca Pedersini; Sara Piccini; Emanuela Morenghi; Deborah Cosentini; Paolo Zucali; Rosalba Torrisi; Silvio Sporeni; Edda L Simoncini; Roberto Maroldi; Luca Balzarini; Andrea G Lania; Alfredo Berruti
Journal:  J Bone Oncol       Date:  2022-03-09       Impact factor: 4.072

7.  Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.

Authors:  Iain Phillips; Syed I A Shah; Trinh Duong; Paul Abel; Ruth E Langley
Journal:  Oncol Hematol Rev       Date:  2014

8.  Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study--how useful is the current clinical gold standard for fracture risk?

Authors:  Hannah C P Wilson; Paul D Abel; S Imran A Shah
Journal:  Clin Interv Aging       Date:  2015-10-19       Impact factor: 4.458

Review 9.  Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion.

Authors:  Daniele Santini; Alfredo Berruti; Massimo Di Maio; Giuseppe Procopio; Sergio Bracarda; Toni Ibrahim; Francesco Bertoldo
Journal:  ESMO Open       Date:  2020-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.